These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32612058)

  • 1. [Evaluation of the Tolerability of Gemcitabine and Cisplatin Combination Chemotherapy with a Small Quantity of Replacement Fluid for Biliary Tract Cancer].
    Ichimura T; Nawata S; Ichikura D; Murakami K; Usuda M; Kawashima W; Minemura A; Sasaki T
    Yakugaku Zasshi; 2020; 140(7):929-936. PubMed ID: 32612058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial safety and efficacy of cisplatin and gemcitabine combination chemotherapy for unresectable biliary tract cancer.
    Shibata Y
    Gan To Kagaku Ryoho; 2014 Dec; 41(13):2599-602. PubMed ID: 25596055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
    Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
    Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma.
    Naiki T; Sugiyama Y; Tasaki Y; Iida K; Etani T; Hamamoto S; Nagai T; Nozaki S; Ando R; Kawai N; Yasui T
    Oncology; 2020; 98(9):612-620. PubMed ID: 32485713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
    Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
    Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer.
    Sasaki T; Isayama H; Nakai Y; Takahara N; Akiyama D; Yagioka H; Kogure H; Matsubara S; Ito Y; Yamamoto N; Sasahira N; Hirano K; Toda N; Tada M; Koike K
    Chemotherapy; 2013; 59(2):106-11. PubMed ID: 24029777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer.
    Kobayashi S; Ueno M; Ohkawa S; Irie K; Goda Y; Morimoto M
    Oncology; 2014; 87(1):30-9. PubMed ID: 24969038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
    Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
    Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
    World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for biliary tract cancer: real-world experience in a single institute.
    Maeda O; Ebata T; Shimokata T; Matsuoka A; Inada-Inoue M; Morita S; Takano Y; Urakawa H; Miyai Y; Sugishita M; Mitsuma A; Ando M; Mizuno T; Nagino M; Ando Y
    Nagoya J Med Sci; 2020 Nov; 82(4):725-733. PubMed ID: 33311803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
    Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gemcitabine in Combination with Cisplatin in Patients with Unresectable Advanced or Recurrent Biliary Tract Cancer--A Multicenter Prospective Observational Study in Fukuoka].
    Yamashita Y; Sirabe K; Kawabe K; Fujimori N; Hisano T; Okabe Y; Akiyama T; Ueki T; Horiuchi H; Yamaguchi H; Ito T; Suga H; Funakosi A
    Gan To Kagaku Ryoho; 2015 Oct; 42(10):1185-9. PubMed ID: 26489546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis.
    Wu CE; Hsu HC; Shen WC; Lin YC; Wang HM; Chang JW; Chen JS
    Chang Gung Med J; 2012; 35(5):420-7. PubMed ID: 23127347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.